Obesity Meds and Research News Publishes a Series of Theme Newsletters on Weight Loss Drug Development

Share Article

OMR has published a report on weight loss drug development. A series on developmental diabetes drugs, and botanical and supplement research is planned for later in the year.

Obesity Meds and Research News (OMR) has published a series of newsletters featuring monographs on clinical and preclinical compounds for the treatment of obesity. In February, OMR provided detailed analysis on the progress of 18 drugs in phase I through III testing, in March highlights from the BIOS Advances in Obesity conference, and in April details on dozens of preclinical compounds.

The OMR web site includes a customized database of over 130 investigational weight loss and diabetes drugs, with links to exclusive OMR analyses, scientific journal articles, conference abstracts, monthly status reports, and other vital information. Later this year OMR will produce two additional series, the first on clinical and preclinical diabetes drugs, and a second on botanical and supplement research.

OMR makes it easy to follow metabolic disease drug development. Investigational drugs can be followed by compound name, mechanism, or by pharmaceutical company. Archives are available back to 1997. OMR monographs will keep you abreast of which compounds are promising and moving forward, which are likely to fail -- and why. Samples available.

OBESITY MEDS AND RESEARCH NEWS is a subscriber-supported advertisement-free newsletter with the latest information on obesity medications, weight loss and diet studies written for professionals and patients. In addition to the monthly newsletter, OMR maintains a drug database, and two subscriber bonuses, OBESITY 101, a primer on obesity basics, and OMR OBESITY UPDATE, a monthly literature overview. The OMR pages contain in-depth information on medications coming out within the next few years like Acomplia (rimonabant), and others in earlier stages of development. The site also has information on medications in use including phentermine, Meridia (sibutramine), and Xenical (orlistat).


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Barbara Hirsch
Visit website